These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Coronary thrombolysis in acute myocardial infarction. Initial experience with an intravenous thrombolytic agent]. Martínez Ríos MA; Cárdenas M; Gil M; Iturbe I; Alarcón A; Soní J Arch Inst Cardiol Mex; 1984; 54(1):3-9. PubMed ID: 6372717 [TBL] [Abstract][Full Text] [Related]
23. An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Timmis AD; Griffin B; Crick JC; Flax JS; Sowton E Drugs; 1987; 33 Suppl 3():146-50. PubMed ID: 3315582 [TBL] [Abstract][Full Text] [Related]
24. Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States. Anderson JL Drugs; 1987; 33 Suppl 3():154-62. PubMed ID: 3315584 [TBL] [Abstract][Full Text] [Related]
25. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial Study Group. Lancet; 1990 Feb; 335(8687):427-31. PubMed ID: 1968167 [TBL] [Abstract][Full Text] [Related]
26. Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection. Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW Ann Intern Med; 1986 Mar; 104(3):304-10. PubMed ID: 3511819 [TBL] [Abstract][Full Text] [Related]
27. Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Kasper W; Meinertz T; Wollschläger H; Bonzel T; Chen C; Hofmann T; Zeiher A; Drexler H; Just H Drugs; 1987; 33 Suppl 3():112-6. PubMed ID: 3315575 [TBL] [Abstract][Full Text] [Related]
28. [Myocardial revascularization in the developing phase of myocardial infarction using intracoronary thrombolytic therapy]. Puel J; Miquel JP; Massabuau P; Cassagneau B; Miluau S; Fauvel JM; Bounnoure JP Rev Med Univ Navarra; 1984 Dec; 28(4):43-6. PubMed ID: 6528151 [TBL] [Abstract][Full Text] [Related]
30. Electrocardiographic and enzymatic infarct size in a randomised study of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Hackworthy RA; Sorensen SG; Menlove RL; Anderson JL Drugs; 1987; 33 Suppl 3():198-208. PubMed ID: 3315592 [TBL] [Abstract][Full Text] [Related]
31. Improved left ventricular function in myocardial infarction following intravenous thrombolytic therapy with acylated plasminogen activator. Ovsyshcher I; Silber H; Hausman MI; Margolis G; Gueron M Angiology; 1990 Feb; 41(2):133-8. PubMed ID: 2407157 [TBL] [Abstract][Full Text] [Related]
32. Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction. Rothbard RL; Anderson JL; Fitzpatrick PG; Hakworthy RA; Sorensen SG; Marder VJ Clin Cardiol; 1990 Mar; Suppl 5():V11-4; discussion V27-32. PubMed ID: 2182234 [TBL] [Abstract][Full Text] [Related]
33. Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction. Jackson D Drugs; 1987; 33 Suppl 3():104-11. PubMed ID: 3315574 [TBL] [Abstract][Full Text] [Related]
34. How should intravenous thrombolytic agents for acute myocardial infarction be selected? Topol EJ Cardiovasc Clin; 1990; 21(1):57-75; discussion 76-8. PubMed ID: 2143103 [No Abstract] [Full Text] [Related]
36. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction. Monk JP; Heel RC Drugs; 1987 Jul; 34(1):25-49. PubMed ID: 3308411 [TBL] [Abstract][Full Text] [Related]
37. [Thrombolysis in acute myocardial infarct: prerequisites, current experiences and remaining problems]. Rapold HJ Schweiz Med Wochenschr; 1986 Aug; 116(33):1074-87. PubMed ID: 3094141 [TBL] [Abstract][Full Text] [Related]
38. Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction. Anderson JL Am J Cardiol; 1989 Jul; 64(2):12A-17A; discussion 24A-26A. PubMed ID: 2662737 [TBL] [Abstract][Full Text] [Related]
39. [Socioeconomic implications of the practice of thrombolysis in the acute stage of myocardial infarction]. Herve C; Castiel D; Gaillard M; Daussac C; Leroux V; Jan F; Castaigne A Arch Mal Coeur Vaiss; 1989 Mar; 82(3):353-8. PubMed ID: 2502091 [TBL] [Abstract][Full Text] [Related]
40. Anistreplase for acute coronary thrombosis. Med Lett Drugs Ther; 1990 Feb; 32(812):15-6. PubMed ID: 2406552 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]